1800-272-662
Shopping Cart 0
countryflagAU
Login

Somnomed Ltd

Healthcare AU SOM

0.66AUD
-(-%)

Last update at 2026-03-13T03:49:00Z

Day Range

0.660.66
LowHigh

52 Week Range

0.370.94
LowHigh

Fundamentals

  • Previous Close 0.66
  • Market Cap144.49M
  • Volume24159
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA3.68M
  • Revenue TTM118.50M
  • Revenue Per Share TTM0.55
  • Gross Profit TTM 70.87M
  • Diluted EPS TTM-0.01

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -0.76386M -11.27063M -7.04526M -3.49570M -0.73390M
Minority interest - - - - -
Net income -3.45633M -12.24173M -7.99904M -4.43697M -1.19301M
Selling general administrative 20.19M 18.01M 14.15M 13.81M 11.21M
Selling and marketing expenses 22.91M 26.18M 24.49M 19.74M 15.58M
Gross profit 66.73M 55.13M 45.77M 39.15M 33.90M
Reconciled depreciation - 5.78M 5.12M 3.94M 3.84M
Ebit -0.31101M -8.10386M -4.41856M -3.41166M -0.26471M
Ebitda 1.58M -2.32861M 0.70M 0.52M 3.57M
Depreciation and amortization 1.89M 5.78M 5.12M 3.94M 3.84M
Non operating income net other - - - - -
Operating income 3.62M -8.32946M -4.07263M -4.13146M -0.65138M
Other operating expenses 107.88M 99.98M 87.69M 76.71M 63.36M
Interest expense 0.40M 3.17M 2.63M 0.38M 0.47M
Tax provision 2.69M 0.97M 0.82M 0.93M 0.35M
Interest income - 0.03M 0.00201M 0.00043M 0.00395M
Net interest income - -3.13670M -2.62469M -0.37990M -0.46523M
Extraordinary items - 0.00000M -0.13214M -0.01066M -0.10995M
Non recurring - - - - -
Other items - - - - -
Income tax expense 2.69M 0.97M 0.82M 0.93M 0.35M
Total revenue 111.49M 91.65M 83.62M 72.58M 62.71M
Total operating expenses 63.11M 57.60M 49.84M 43.28M 34.56M
Cost of revenue 44.76M 36.52M 37.85M 33.43M 28.80M
Total other income expense net -4.38095M -2.94117M -2.97263M 0.64M -0.08252M
Discontinued operations - - -0.13214M -0.01066M -0.10995M
Net income from continuing ops - -12.24173M -7.86690M -4.42630M -1.08306M
Net income applicable to common shares -3.45633M -12.24173M -7.99904M -4.43697M -1.19301M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 80.97M 69.80M 62.49M 58.09M 56.17M
Intangible assets 1.56M - 12.48M 9.41M 2.32M
Earning assets - - - - -
Other current assets 7.23M 4.43M 0.32M 0.27M 0.13M
Total liab 34.58M 24.78M 40.09M 30.31M 24.01M
Total stockholder equity 46.39M 45.02M 22.40M 27.79M 32.16M
Deferred long term liab - - 9.67M 6.62M 1.25M
Other current liab 6.41M 4.05M 3.20M 11.18M 5.86M
Common stock 119.96M 110.23M 74.27M 74.27M 74.26M
Capital stock - - 74.27M 74.27M 74.26M
Retained earnings -77.93664M -74.53666M -62.29494M -54.29589M -49.85891M
Other liab - - 0.79M 1.18M 0.86M
Good will 7.05M 6.34M 6.49M 6.04M 6.26M
Other assets - - 3.25M 9.83M 4.37M
Cash 17.29M 16.18M 11.96M 15.64M 21.11M
Cash and equivalents - - 11.96M 15.64M 21.11M
Total current liabilities 28.58M 19.94M 18.36M 23.77M 16.20M
Current deferred revenue - 0.18M 0.00153M -6.65729M -1.95602M
Net debt -9.26757M -9.45907M 11.55M -3.63400M -12.20223M
Short term debt 2.83M 2.60M 2.57M 6.66M 1.96M
Short long term debt - - 0.31M 4.88M -
Short long term debt total 8.03M 6.72M 23.51M 12.01M 8.91M
Other stockholder equity - 9.33M -21.76422M -29.76327M -34.20024M
Property plant equipment - - 12.73M 9.12M 10.34M
Total current assets 43.14M 35.14M 27.50M 30.32M 34.13M
Long term investments - - - - -
Net tangible assets - - 13.10M 18.96M 24.83M
Short term investments - - - - -
Net receivables 11.19M 8.24M 8.71M 8.93M 8.09M
Long term debt - - 16.36M 2.01M 2.35M
Inventory 7.43M 6.29M 4.10M 3.09M 2.33M
Accounts payable 19.34M 13.11M 12.59M 12.59M 10.33M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 4.37M - 10.43M 7.81M 7.76M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 15.26M 13.97M -22.03566M -17.94336M -17.66934M
Deferred long term asset charges - - - - -
Non current assets total 37.83M 34.67M 35.00M 27.78M 22.04M
Capital lease obligations - - 6.84M 5.12M 6.56M
Long term debt total - - 20.94M 5.35M 6.95M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments - -5.34100M -6.41458M 0.32M -0.27147M
Change to liabilities - - -1.88181M 2.34M 1.99M
Total cashflows from investing activities -3.97685M -5.34100M -6.41458M -8.47177M -4.36857M
Net borrowings - -16.78850M 6.61M 2.09M -7.20332M
Total cash from financing activities -3.38486M 16.68M 6.61M 2.09M -6.80435M
Change to operating activities - - 0.03M 0.70M 1.06M
Net income -3.45633M -12.24173M -7.99904M -4.43697M -1.19301M
Change in cash 1.11M 4.22M -3.68792M -5.46551M -9.06440M
Begin period cash flow 16.18M 11.96M 15.64M 21.11M 30.17M
End period cash flow 17.29M 16.18M 11.96M 15.64M 21.11M
Total cash from operating activities 7.78M -6.33277M -3.88020M 1.86M 2.71M
Issuance of capital stock - 38.08M - - 0.40M
Depreciation 5.74M 6.80M 3.97M 3.38M 3.29M
Other cashflows from investing activities -1.55559M -3.95406M 0.00000M 0.32M -0.23647M
Dividends paid - - - - -
Change to inventory -0.68774M -2.19863M -1.01080M -0.75944M -0.08770M
Change to account receivables -4.17462M -1.43166M 0.37M -0.37342M -2.86074M
Sale purchase of stock 0.00000M -2.07416M 0.00000M 0.00000M 0.40M
Other cashflows from financing activities -0.04439M -2.53666M 12.95M 2.09M -7.20332M
Change to netincome - - 1.68M 0.46M -0.03839M
Capital expenditures 2.42M 1.39M 6.41M 8.79M 4.13M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -4.23142M -1.07310M -0.64406M -1.13286M -2.94844M
Stock based compensation 1.95M 0.08M 1.04M 1.19M 0.07M
Other non cash items 7.78M 0.10M 0.15M 2.92M 0.61M
Free cash flow 5.36M -7.71971M -10.29479M -6.93064M -1.42633M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
SOM
Somnomed Ltd		 - -% 0.66 - 38.76 1.22 2.89 1.12 23.52
COH
Cochlear Ltd		 -4.74 2.65% 174.42 33.10 26.39 4.88 6.04 5.59 23.13
4DX
4DMEDICAL Ltd		 -0.15 3.55% 4.07 - - 401.92 37.59 417.71 -7.2899
AVR
Anteris Technologies Global Corp		 - -% 9.10 - - 475.96 166.77 334.65 -5.1986
PNV
Polynovo Ltd		 - -% 0.94 94.00 30.21 4.66 7.81 4.68 93.96

Reports Covered

Stock Research & News

View All

Profile

SomnoMed Limited, together with its subsidiaries, produce and sells devices for the oral treatment of sleep related disorders in the Asia Pacific region, North America, and Europe. It provides SomnoDent Avant, as well as SomnoDent Classic, SomnoDent Flex, and SomnoDent Fusion are offered for the treatment of obstructive sleep apnea. The company also offers SomMorning Repositioner, a product designed to help return patient's mandible back to its pre-treatment centric position; SomnoBrux splint, a custom fit, acrylic splint for patient's upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs, which are cleaning tablets to clean oral appliances. SomnoMed Limited was incorporated in 1987 and is headquartered in Crows Nest, Australia.

Somnomed Ltd

20 Clarke Street, Crows Nest, NSW, Australia, 2065

Key Executives

Name Title Year Born
Mr. Neil Verdal-Austin B.Com., C.A. Global CEO, MD & Director NA
Mr. Hervé Fiévet Global Chief Financial Officer NA
Mr. Mark Harding VP of Global Marketing NA
Mr. Matthew Conlon Exec. VP Sales & Marketing - North America NA
Mr. Marco Van Kleef VP of Marketing & Sales - Europe NA
Dr. Jagdeep Bijwadia Chief Medical Officer NA
Mr. Terence A. Flitcroft B.Com., B.Comm., C.A., CA, SF FIN Company Sec. 1959
Dr. Peter Spencer MBA Ph.D., MAICD Gen. Mang. of Operations 1956
Mr. Christopher Bedford VP of Global Production and Product Devel. NA
Mr. Mark Harding Vice President of Global Marketing NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.